Bridgewater Advisors’s AstraZeneca AZN Stock Holding History

Bridgewater Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$866K	Sell	4,615 -870	-16%	-$168K	0.05%	157
2025 Q4	$993K	Buy	5,485 +175	+3%	+$30.7K	0.06%	138
2025 Q3	$890K	Buy	5,310 +80	+2%	+$12.1K	0.06%	146
2025 Q2	$774K	Buy	5,230 +147	+3%	+$20.6K	0.06%	169
2025 Q1	$729K	Buy	+5,083	New	+$735K	0.06%	160
2024 Q4	–	Sell	-5,167	Closed	-$777K	–	130
2024 Q3	$777K	Buy	5,167 +10	+0.2%	+$1.61K	0.08%	102
2024 Q2	$810K	Buy	+5,157	New	+$776K	0.1%	94

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Bridgewater Advisors's AZN Position: Q1 2026 in Review

Bridgewater Advisors reduced its AstraZeneca (AZN) stake by 16% in Q1 2026, selling an estimated $168K and leaving 4,615 shares worth $866K. The position accounts for 0.05% of the portfolio, ranked #157.

Bridgewater Advisors first reported a position in AZN in Q2 2024 and has held it in 7 quarters since. The position peaked at $993K in Q4 2025. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Bridgewater Advisors held 4,615 shares of AstraZeneca worth $866K as of Q1 2026.
Bridgewater Advisors sold 870 AstraZeneca shares in Q1 2026, an estimated $168K.
AstraZeneca made up 0.05% of Bridgewater Advisors's portfolio in Q1 2026, its #157 holding.
Bridgewater Advisors first reported a position in AstraZeneca in Q2 2024 and has held it in 7 quarters since.
Bridgewater Advisors's AstraZeneca position peaked at $993K in Q4 2025.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Bridgewater Advisors's 13F filing for Q1 2026, filed 14 May 2026.